Resident Rounds: Part III – Case Report: Crohn’s Disease Presenting as Granulomatous Cheilitis

February 2016 | Volume 15 | Issue 2 | Features | 251 | Copyright © February 2016


Bryce L. Desmond DO, R. Scott Thomas DO, and Stephanie S. Howerter DO

Western University of Health Sciences – Silver Falls Dermatology, Salem, OR

table 1
recent biologic immunomodulators (infliximab, adalimumab, certolizumab, vedolizumab, natilizumab, ustekinumab) target inflammatory cytokines. While some of these drugs are already approved to treat CD, others are currently in trials. The latter medications are emerging as standard of care due to their rapid onset of improvement and ability to maintain remission.4

DISCLOSURES

The authors have no conflicts of interest to declare.
table 2

REFERENCES

  1. Bouhnik Y, Scemama G, Taï R, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347(8996):215-219.
  2. Harty S, Fleming P, Rowland M, et al. A prospective study of the oral manifestations of Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(9):886-891.
  3. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn’s diease. An analysis of 79 cases. J Clin Gastroenterol. 1991;13(1):29-37.
  4. Randall CW, Vizuete JA, Martinez N, et al. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn’s disease. Therap Adv Gastroenterol. 2015;8(3):143-159.
  5. Sandborn WJ, Feagan B. Review article: mild to moderate Crohn’s disease – defining the basics for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18(3):263-277.
  6. Woo VL. Oral manifestations of Crohn’s disease: a case report and review of the literature. Case Rep Dent. 2015;2015:830472.

CONCLUSION

AUTHOR CORRESPONDENCE

Bryce L. Desmond DO……................................... bdesmond@silverfallsderm.net
Close Menu